Preferred Label : relugolix;
MeSH note : structure in first source;
CISMeF synonym : TAK 385; 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)pyrimidin-6-yl)phenyl)-3-methoxyurea;
MeSH hyponym : TAK385; TAK-385;
Is substance : O;
Origin ID : C561634;
UMLS CUI : C3896936;
ATC code(s)
ATC code(s)
Currated CISMeF NLP mapping
MeSH indexing information
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
Semantic type(s)
UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3530112/fr/ryeqo-relugolix/estradiol/acetate-de-norethisterone-endometriose
2024
false
false
false
France
administration, oral
administration, oral
drug combinations
drug combinations
treatment outcome
treatment outcome
insurance, health, reimbursement
insurance, health, reimbursement
estradiol
estradiol
relugolix
relugolix
relugolix, estradiol and norethisterone
relugolix, estradiol and norethisterone
evaluation of the transparency committee
evaluation of the transparency committee
evaluation of the transparency committee
endometriosis
endometriosis
endometriosis
Norethindrone Acetate
Norethindrone Acetate
Norethindrone Acetate
---
https://www.has-sante.fr/jcms/p_3554612/fr/ryeqo-relugolix/estradiol/acetate-de-norethisterone-endometriose-fibromes-uterins
2024
false
false
false
France
drug combinations
drug combinations
drug combinations
drug combinations
treatment outcome
treatment outcome
treatment outcome
treatment outcome
insurance, health, reimbursement
insurance, health, reimbursement
insurance, health, reimbursement
insurance, health, reimbursement
relugolix
relugolix
relugolix, estradiol and norethisterone
estradiol
estradiol
administration, oral
administration, oral
fibroid uterus
fibroid uterus
evaluation of the transparency committee
evaluation of the transparency committee
evaluation of the transparency committee
evaluation of the transparency committee
leiomyoma
leiomyoma
leiomyoma
leiomyoma
endometriosis
endometriosis
endometriosis
endometriosis
Norethindrone Acetate
Norethindrone Acetate
Norethindrone Acetate
Norethindrone Acetate
---
https://www.has-sante.fr/jcms/p_3434157/fr/orgovyx-relugolix-cancer-de-la-prostate-avance-hormonodependant
2023
false
false
false
France
orgovyx
orgovyx
orgovyx
neoplasms, hormone-dependent
neoplasms, hormone-dependent
neoplasms, hormone-dependent
treatment outcome
treatment outcome
treatment outcome
insurance, health, reimbursement
insurance, health, reimbursement
insurance, health, reimbursement
advanced hormone-dependent prostate cancer
advanced hormone-dependent prostate cancer
advanced hormone-dependent prostate cancer
adult
adult
adult
Product containing precisely relugolix 120 milligram/1 each conventional release oral
tablet (clinical drug)
Product containing precisely relugolix 120 milligram/1 each conventional release oral
tablet (clinical drug)
Product containing precisely relugolix 120 milligram/1 each conventional release oral
tablet (clinical drug)
administration, oral
administration, oral
administration, oral
relugolix
relugolix
relugolix
androgen antagonists
androgen antagonists
androgen antagonists
evaluation of the transparency committee
evaluation of the transparency committee
evaluation of the transparency committee
evaluation of the transparency committee
relugolix
relugolix
relugolix
prostatic neoplasms
prostatic neoplasms
prostatic neoplasms
---
https://www.ema.europa.eu/en/medicines/human/EPAR/ryeqo
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
relugolix
relugolix
drug approval
europe
endometriosis
estradiol
estradiol
relugolix, estradiol and norethisterone
Norethindrone Acetate
Norethindrone Acetate
fibroid uterus
administration, oral
risk management
product surveillance, postmarketing
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
---